Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Response to AASLD editorial/message from the president

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Novel Biomarker Discovery in Non-Alcoholic Steatohepatitis (NASH): Translation of Complex Data into Clear Results

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  2. Viral persistence, liver disease and host response in Hepatitis C-like virus rat model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Relationship between Genetic Variation at PPP1R3B and Liver Glycogen and Triglyceride Levels

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftHepatology (Baltimore, Md.)
ISSN0270-9139
DOI
StatusE-pub ahead of print - 1 okt. 2018

ID: 55428635